Citation tools
"Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient." Anticancer Research
40.5
(2020):
2813-2819.
Web. 18 April. 2024.